Skip to main content
Home
Knowledge Base
for the National TB Elimination Program - NTEP

Main navigation

  • Home
    • About Us
  • Curriculum
    • Search Courses
  • Knowledge Map
    • Knowledge Map Summary
  • Page Library
    • Content Page Summary
    • Translations
  • Documents

Search

BPaLM: Overview

  1. Home
  2. BPaLM: Overview
  • Burden of DR-TB in India

    H5Content
  • Types of Drug Resistance Tuberculosis -DRTB

    H5Content
  • History of Programmatic Management of Drug Resistant TB [PMDT] in India

    H5Content
  • Newer Anti-TB Drugs

    H5Content
  • Newer Anti-TB Drugs: Pretomanid [Pa]

    H5Content
  • WHO recommendation for newer, shorter, oral regimens

    H5Content
  • BPaLM regimen for DR-TB

    H5Content
  • Evidence for the efficacy of BPaL regimen in DR-TB

    H5Content
  • Rationale for continuation of Moxifloxacin in BPaLM regimen irrespective of FQ resistance

    H5Content
  • Shorter oral Bedaquiline-containing MDR/RR-TB regimen

    H5Content
  • 2024 NTEG Recommendations for DR-TB Management

    H5Content
  • 2024 Updates in DR-TB Management

    H5Content
Cover

This is a overview chapter on PMDT. it discusses various evidence available for newer DR-TB regimens, the rationale for using the combination and brief overview about the newer drugs.

User account menu

  • Log in

This work is licensed under Attribution-NonCommercial 4.0 International